AZD3489

AZD3489 is an orally bioavailable, selective inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). Developed by AstraZeneca, the compound was designed to modulate the intracellular conversion of inactive cortisone to active cortisol, primarily within the liver and adipose tissue. By inhibiting 11β-HSD1, AZD3489 aims to reduce local glucocorticoid signaling, thereby improving insulin sensitivity, reducing hepatic glucose output, and addressing metabolic disturbances associated with type 2 diabetes mellitus and metabolic syndrome. Although it progressed through Phase 1 and Phase 2 clinical evaluations to assess safety, pharmacokinetics, and glycemic control, further development appears to have been halted, reflecting a broader industry trend where 11β-HSD1 inhibitors faced challenges in demonstrating sufficient clinical efficacy compared to existing standards of care.